HPV16 variants distribution in invasive cancers of the cervix, vulva, vagina, penis, and anus
Sara Nicolás-Párraga, Carolina Gandini, Ville Pimenoff, Laia Alemany, Silvia de Sanjosé, F. Xavier Bosch, Ignacio Bravo

To cite this version:

HAL Id: hal-02003091
https://hal.umontpellier.fr/hal-02003091
Submitted on 1 Feb 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Certain human papillomaviruses (HPVs) are associated with certain human tumors. Based on the differential risk and association between infections and invasive cervical cancer (ICC), HPVs are classified into different risk groups [1]. A number of HPVs are considered carcinogenic for humans (group 1) or possibly/probably carcinogenic (groups 2a and 2b, respectively) and are commonly referred to as “high-risk HPVs” [1, 2]. ICC is worldwide the second most common cancer affecting women and responsible...
for approximately 266,000 deaths per year (http://globocan.iarc.fr/Default.aspx). Persistent infection by oncogenic HPVs is considered a pre-requisite for the development of virtually all ICCs [3]. For this reason, the most extensive studies on HPVs have addressed cervical lesions and tumors [4]. A similar repertoire of HPVs may also be responsible for different fractions of other anogenital tumors [5], as viral DNA has been detected in malignant proliferations in the penis (33% prevalence) [6, 7], anus (88% prevalence) [7, 8], vulva (29% prevalence) [9], and vagina (74% prevalence) [10].

Oncogenic potential is not evenly distributed among oncogenic HPVs. Instead, HPV prevalence largely differs between types and between geographical regions, and the probability of progression from a clinically asymptomatic cervical infection to ICC is different for different HPVs [11, 12]. HPV16 is the most frequently detected HPV in all cervical infections, from normal cytology to ICC, in all world regions [11, 12]. HPV16 is also the most oncogenic HPV, responsible for 61% of all ICCs worldwide [4] and for even higher fractions of other HPV-associated anogenital carcinomas [6, 9, 10]. The biological reasons underlying the increased prevalence and oncogenicity of HPV16 compared with other closely related viruses, for example, the sister viruses HPV31 and HPV35, remain unclear [13].

Sequence diversity within HPV types is described in terms of viral variants [14]. The best classification for HPV16 variants has been proposed by Burk and coworkers, describing four lineages and a number of sublineages and applying an alphanumeric code, for example, HPV16_A4 [15]. Further, a large body of experimental research on the differential biological activities of HPV16 variants has focused on the E6 gene, especially on the T350G polymorphism, corresponding to the L83V amino acid substitution in the E6 oncoprotein. The initial literature described 350T as the “prototype,” found in the “European” HPV16 variant, and the 350G allele as the “nonprototype,” found in “non-European” HPV16 variants. However, the T350G polymorphism is found in different HPV16 variant lineages and is not a specific marker of any of them [16].

Papillomavirus variants are genetically very close, with above 98% nucleotide identity [14], but nonetheless HPV16 variants are suggested to differ in their oncogenic potential [17]. Particularly, the E6 T350G polymorphism has been associated with differential persistence and risk of progression to precancerous cervical lesions [17, 18].

The objective of this study was to characterize the viral component in a comprehensive set of invasive tumors of the cervix, vulva, vagina, penis, and anus, encompassing 35 countries within three continents. We aimed to analyze the differential prevalence of HPV16 variants as well as of the intensively studied T350G polymorphism as a function of the anatomical location of the lesion, the geographical origin of the samples, and the age at cancer diagnosis.

Materials and Methods

Samples

Samples analyzed in this study stem from a formalin-fixed paraffin-embedded (FFPE) sample repository from the Catalan Institute of Oncology (ICO), Barcelona, Spain, designed and constructed for the assessment of HPVs contribution to a number of anogenital human tumors [4, 6, 8–10]. All samples were tested for the presence of tumor tissue and for the presence of HPVs DNA using the SPF10-LiPA25 protocol, capable of genotyping HPV6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, and 74 (version 1; Laboratory Biomedical Products, Rijswijk, the Netherlands). For this study, we selected 711 invasive squamous cell carcinomas showing exclusively the presence of HPV16 DNA after LiPA25 genotyping. This data set consisted of samples from the cervix (n = 170), vulva (n = 128), vagina (n = 121), penis (n = 119), and anus (n = 172), spanning 35 different countries within three geographical regions: Europe, Central/South America, and Asia (Table S1).

Specimens were received anonymously and allocated a unique identification number upon reception, and the respective local and ICO ethic committees approved all the study protocols.

Identification and selection of the most informative regions

The most variable regions in the HPV16 genome were identified to maximize sequence diversity and phylogenetic signal in the targeted DNA fragments. We retrieved 109 HPV16 complete genome sequences from GenBank. Coding regions were aligned at the amino acid level with Muscle 3.7 [19] (http://www.ebi.ac.uk/Tools/msa/muscle/), while the upstream regulatory region (URR) was aligned at nucleotide level. Phylogenetic inference was performed at nucleotide level for each alignment, as well as for the concatenated full-length aligned genome, under a maximum likelihood framework using RAxML v7.2.8 [20] (http://www.exelixis-lab.org/) and the GTR+Γα substitution model. Robustness of tree individual nodes was assessed by bootstrap resampling analysis, as determined with the -autoMRE command [21]. Using the full-length genome data and the -J MR_DROP command [22], three rogue taxa were identified to show inconsistent positions during bootstrapping and were excluded from further analyses. The final alignment for the full-length genome comprised
technologies, Alcobendas, Spain), 2.0 mmol/L MgCl₂, S. Nicolás-Párraga et al. © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Γ 4 of HPV16 genetic variability using an Evolutionary LCR short fragments were placed in the global context, Phylogenetic relationships of the amplified E6, proteinase K, and stored at −20°C until use. A 1:10 water dilution of this DNA solution was used for downstream processing. PCR primers were designed to target-specific HPV16 genome regions, so that well-described lineage-specific polymorphisms were covered by the corresponding amplicons (Table S2). We also used primers previously designed by Larsson and coworkers [23] to span two positions in the E6 gene that have been thoroughly analyzed in several studies (i.e., nt 131 and 350, reference sequence GenBank: NC_001526). All PCR reaction mixtures contained: 0.125 U/μL AmpliTaq Gold® DNA Polymerase (Life Technologies, Alcobendas, Spain), 2.0 mmol/L MgCl₂, 0.2 μmol/L deoxynucleotides triphosphate (Life Technologies, Alcobendas, Spain), 0.2 μmol/L forward and reverse primer (Biolegio, Nijmegen, The Netherlands), and 5 μL DNA solution. PCR conditions were 95°C for 10 min; 40 cycles of 30 sec at 94°C, 30 sec at 58°C, 30 sec at 72°C; plus 7-min final extension at 72°C. PCR products were Sanger-sequenced at Genoscreen (Lille, France) in both strands using four pairs of primers. (Table S2).

Phylogenetic analyses

Phylogenetic relationships of the amplified E6, L2, and LCR short fragments were placed in the global context of HPV16 genetic variability using an Evolutionary Placement Algorithm on RAxML v7.2.8 with the GTR+Γκ model [19, 20]. The algorithm provides likelihood weights for placing the partial sequences into the different nodes in the reference tree, in our case based on the pruned full-length genome alignment described above. Sequences obtained from our samples were incorporated into the reference alignment with MAFFT v7, and their phylogenetic placement was individually inferred with the -f v command in RAxML [21]. We integrated the results for all nodes and used 0.7 as a likelihood cutoff value to assign each sample into a specific variant lineage, namely A1–3, A4, B, C, and D (Table S3, Fig. S1). Using the 0.7 cutoff, 12 samples (1.7%) could only be classified as belonging to the A lineage and were subsequently classified as HPV16_A1-3 using a 0.6 cutoff value (Table S3).

Statistical analyses

A generalized linear model (GLM) with a Poisson distribution for count data and a log-link function was used to analyze the relationship between HPV16 variants prevalence with the two variables of interest: anatomical location and geographical origin. We explored as well the contribution of all double and triple interactions. Significance level was set at α value of 0.05. Analyses were performed using R in RStudio v0.98.939 (RStudio, Inc.). To corroborate the GLM results, differences in HPV16 variant distribution stratifying by anatomical location or by geographical origin were statistically assessed by means of Pearson’s chi-square test and of Fisher’s test, respectively. Prevalence ratios (PRs) of HPV16 variants among invasive anogenital cancers between Europe and Central/South America or Asia were estimated using Poisson multivariate regression model with robust variance. The different HPV16 variant lineages (i.e., A1–3, A4, and D) were used as dichotomous variables.

Distribution of the polymorphic site T350G within HPV16_A1 variants was assessed by Pearson’s chi-square test when stratified by geographical origin and by Fisher’s test when stratified by anatomical location. To assess the possible differential prevalence of the T|G alleles, we estimated the frequency of this polymorphism within HPV16_A1-3 variants for all anatomical locations for samples from Europe and Central/South America (Table 3). By focusing on the HPV16_A1-3 variants, we aimed to avoid the possible different epistatic interactions of the T|G alleles with the genetic background of each HPV16 variant, because the E6 350 position is also polymorphic T|G in HPV16_B, monomorphic T in HPV16_C, and monomorphic G in HPV16_D [16]. Asian cases were excluded from this analysis due to the small number of samples.

Cancer registry data show that cervical cancers are diagnosed earlier than other anogenital cancers associated with HPVs [6, 8–10]. Also, cancers caused by HPV16 are diagnosed earlier than cancers in the same anatomical location caused by other HPVs [4]. To disentangle the effects of virus genetics and anatomical location of the lesion on the age at diagnosis, we have followed a top-down approach, analyzing first age at cancer diagnosis for all HPV-related anogenital cancers available from our full clinical data set [4, 6, 8, 9], then for all cases exclusively linked to HPV16, and finally for all cases exclusively linked to HPV16_A1-3 (Fig. 2). For ages at tumor diagnosis, central values were estimated with the median, dispersion was estimated with the median absolute deviation, and differences were assessed.
by Wilcoxon–Mann–Whitney test. Bonferroni correction for multiple comparisons was used when applicable.

Results

Choice of informative regions and sample set description

We identified, in decreasing order, E4, E5, LCR, L2, E2, and E6 as the most informative regions in the HPV16 genome to perform phylogenetic inference (Fig. S2). PCRs were designed for each of these six genomic regions, and the LCR, L2, and E6 targets rendered the best results in terms of amplicon quality and suitability for Sanger sequencing, as well as for the number of samples that tested positive. The final sample set comprised three continents (Europe, Central/South America, and Asia) and five anatomical sites (cervix, vulva, vagina, anus, and penis) (Table 1; Table S1). From 711 initially suitable amplicons, we were able to confidently classify 692 (97.3%) as belonging to HPV16_A1-3, A4, B, C, or D following an evolutionary placement algorithm (Table S3). Only nine samples belonged within the B or C lineages. Given the low numbers for both B and C lineages in our sample set, these sequences were not included in further analyses.

Geographical origin and anatomical location of the HPV16 variant distribution

The association between HPV16_A1-3, A4, and D variants (n = 683) with anatomical location and geographical origin was assessed using a GLM analysis. The model that fitted best our observations for the complete data set included the predictors “Geographical origin,” “Anatomical location,” and “Variant” (AIC = 225.88; Table S4). All predictors and their two-by-two interactions contributed significantly to the model (P < 0.0001 in all cases), but the triple interaction did not provide additional explanatory power (P = 0.36). The GLM analysis fitted very well our experimental data, as only <1.4% of all variance in HPV16 variant distribution remained unexplained by the model (Table S4). In our data set, 14.1% of the global variability arose from differential coverage of the three geographical regions (n = 342 for Europe, n = 261 for Central/South America, and n = 80 for Asia), and only 1.7% arose from differential coverage of the five anatomical origins analyzed (n = 163 for cervix, n = 121 for vulva, n = 114 for vagina, n = 115 for penis, and n = 170 for anus). Thus, the GLM approach allowed us to estimate and account for possible biases associated with design asymmetries in our data. We confirmed further the GLM results by estimating prevalence ratios for the different HPV16 variants stratifying by geography (Table 2) and by using a chi-square test after stratifying for geography and a Fisher’s test after stratifying by anatomical location of the samples (Table S5).

We estimated that 68.2% of all variation in HPV16 variants abundance corresponded to actual differences in variant prevalence alone (P < 2.2e−16; Table S4). Globally, HPV16_A1-3 was by far the most prevalent variant, with an overall prevalence of 95% in Europe, 86% in Central/South America, and 61% in Asia (F, Table 2). We

Table 1. Anatomical location and geographical distribution of amplified and classified samples.

<table>
<thead>
<tr>
<th>Anatomical location</th>
<th>Europe Amplified</th>
<th>Europe Classified</th>
<th>Central/South America Amplified</th>
<th>Central/South America Classified</th>
<th>Asia Amplified</th>
<th>Asia Classified</th>
<th>Total amplified</th>
<th>Total classified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervix</td>
<td>72</td>
<td>70</td>
<td>71</td>
<td>69</td>
<td>27</td>
<td>26</td>
<td>170</td>
<td>165</td>
</tr>
<tr>
<td>Vulva</td>
<td>68</td>
<td>68</td>
<td>36</td>
<td>32</td>
<td>24</td>
<td>23</td>
<td>128</td>
<td>123</td>
</tr>
<tr>
<td>Vagina</td>
<td>61</td>
<td>60</td>
<td>51</td>
<td>48</td>
<td>10</td>
<td>9</td>
<td>122</td>
<td>117</td>
</tr>
<tr>
<td>Penis</td>
<td>74</td>
<td>73</td>
<td>42</td>
<td>40</td>
<td>3</td>
<td>2</td>
<td>119</td>
<td>115</td>
</tr>
<tr>
<td>Anal</td>
<td>79</td>
<td>79</td>
<td>72</td>
<td>72</td>
<td>21</td>
<td>21</td>
<td>172</td>
<td>172</td>
</tr>
<tr>
<td>Total</td>
<td>354</td>
<td>350</td>
<td>272</td>
<td>261</td>
<td>85</td>
<td>81</td>
<td>711</td>
<td>692</td>
</tr>
</tbody>
</table>

Table 2. Prevalence ratio (PR) of HPV16 variants between Europe and Central/South America or Asia.

<table>
<thead>
<tr>
<th>Variant</th>
<th>Europe (%)</th>
<th>Central/South America (%)</th>
<th>Asia (%)</th>
<th>Europe vs. Central/South America</th>
<th>Europe vs. Asia</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1-3</td>
<td>324 (94.7)</td>
<td>225 (86.2)</td>
<td>49 (61.3)</td>
<td>Ref</td>
<td>Ref</td>
</tr>
<tr>
<td>A4</td>
<td>4 (1.2)</td>
<td>1 (0.4)</td>
<td>26 (32.5)</td>
<td>0.49 0.85–2.84</td>
<td>6.60 4.90–8.88</td>
</tr>
<tr>
<td>D</td>
<td>14 (4.1)</td>
<td>35 (13.4)</td>
<td>5 (6.2)</td>
<td>1.75 1.43–2.15</td>
<td>2.00 0.90–4.45</td>
</tr>
<tr>
<td>Wald’s test</td>
<td></td>
<td></td>
<td></td>
<td>P &lt; 0.001</td>
<td>P &lt; 0.001</td>
</tr>
</tbody>
</table>
quantified further that 9.0% of all variance in variant distribution was explained by differential association of viral lineages with geography ($P < 2.2e^{-16}$; Table S4). This variation corresponded to a significant 1.7-fold (95% CI: 1.4–2.1) increase of HPV16_D prevalence in Central/South America and to a significant 6.6-fold (95% CI: 4.9–8.9) increase of HPV16_A4 prevalence in Asia, in both cases compared with Europe (Table 2, see also Fig. 1). Finally, 2.8% of all variation in variant distribution corresponded to differential association of viral lineages with anatomical location ($P < 2.1e^{-05}$, Table S4, see also Fig. 1). This variation stemmed from the increased prevalence of HPV16_A4 in vagina and in anus in Asia, where this variant prevailed (Table S5, see also Fig. 1). Differences remained significant even after excluding data from Asia for vagina and penis, both locations with low number of cases (Table S5, see also Fig. 1).

**HPV16 E6 gene T350G polymorphism**

Prevalence for the 350G allele within HPV16_A1-3 ranged between 47% and 59% for Europe and between 59% and 90% for Central/South America. No differences between anatomical locations were observed within each geographical region (respectively, $P = 0.617$ and $P = 0.102$ for Europe and Central/South America). However, HPV16_A1-3 cases from Central/South America showed consistently higher 350G allele frequencies compared with Europe, especially for cervical ($P = 0.015$) and penile ($P < 0.0005$) cancers (Table 3).

**Age at cancer diagnosis**

Cervical cancers showed significantly younger ages at diagnosis compared with other anogenital cancers (early fifties vs. early sixties, $P < 0.0005$) regardless of the onco- genic HPV type or of the HPV16 variant driving the cancer (Fig. 2, see also Table S6). Notably, no significant differences were observed for age at cancer diagnosis among noncervical cancers (Fig. S3, see also Table S7).

**Discussion**

In this study, we have assessed the HPV16 variant diversity in a comprehensive set of invasive tumors of the cervix,
Vulva, vagina, penis, and anus, analyzing the HPV16 variant distribution in 692 invasive squamous cancer samples from Europe, Central/South America, and Asia.

We have quantified for the first time the relative contributions of variant differential abundance, geographical origin, and anatomical location of the anogenital cancers to the observation of differential prevalence distribution of HPV16 variants. Our results show that there are no large differences between HPV16 lineage prevalence values among the anogenital cancers. The most prevalent viral lineage was by far HPV16_A1-3, independently of geographical origin and anatomical location of the samples, with the only exception of anal cancers in Asia, dominated by HPV16_A4, albeit based on small numbers. We have further estimated the contribution of geography and anatomical location to the observed differential HPV16 variant prevalence. The geographical origin of the cancer sample explains roughly 9% of all diversity in viral lineage distribution, and this contribution arises essentially from the increased prevalence of HPV16_A4 in samples from Asia and of HPV16_D in samples from Central/South America. In contrast, the anatomical location of the anogenital cancer explains only <3% of the observed diversity in viral lineages distribution. Indeed, we have not observed significant prevalence differences for HPV16 variants between anatomical locations of the anogenital cancers within Europe or Central/South America. In Asia, however, the higher contribution of HPV16_A4 variant in anogenital cancers exhibited a significant prevalence peak for anal cancers.

Variant distribution and diversity in HPV16 have mainly focused on the uterus cervix [16, 24, 25], but a sound description for viral lineages in other anogenital cancers sites was still wanting. Here, we have characterized the HPV16 variant component in a total of 692 anogenital invasive squamous cancers, including more than 550 cases from the vulva, vagina, penis, or anus. Our results confirm previous results with cervical samples and show further that the repertoire of viral HPV16 variants in anogenital cancers is largely the same regardless of the anatomical location. Consistent with our observations, two previous small studies in Northern Europe (HPV positive total \( N = 40 \); HPV16 positive \( N = 31 \)) and in North America (HPV positive total \( N = 14 \); HPV16 positive \( N = 9 \)) also reported an increased prevalence of HPV16_A1-3 variants in vulvar cancer (\( N = 29/31 \); \( N = 5/9 \) respectively) [26, 27]. Regarding vaginal cancer, the only previous study analyzing HPV16 variants (HPV positive total \( N = 37 \); HPV16 positive total \( N = 26 \)) showed exclusively the presence of HPV16_A1-3 variants in European samples [26]. For anal cancer, a Canadian study (HPV positive total \( N = 96 \); HPV16 positive total \( N = 79 \)) reported around 90% prevalence for HPV16_A variants [28]. Finally, and concerning viral diversity in HPV16-associated penile cancers, an Italian study (HPV positive total \( N = 19 \); HPV16 positive total \( N = 18 \)) showed above 40% prevalence for both HPV16_A1-3 and D variants, along with above 10% minor nonnegligible contribution of HPV16_B variants [29]. However, a Mexican series of penile cancer samples (HPV positive total \( N = 67 \); HPV16 positive total \( N = 57 \)) showed 92% prevalence of HPV16_A1-3 and 8% prevalence of HPV16_D [30]. In certain cases, the use in previous literature of imprecise naming schemes for HPV16 variants hampers a proper comparison. To avoid ambiguity, we have adhered here to the HPV16 variant terminology as standardized by Burk and coworkers [15] and strongly encourage further research on HPV variants to stick to it. Previous HPV16 variant nomenclatures included potentially misleading geographical references (e.g., “European”) or ill-defined arbitrary classifications (e.g., “prototype” or “nonprototype”). The use of a geography-based nomenclature conveys a message of a close match between differential HPV16 variants prevalence and geography, which is not justified neither by the best previously available data [16] nor by our results presented here.

Table 3. HPV16_A1-3 variant distribution of the T350G polymorphic site for Europe and Central-South America and for anatomical location.

<table>
<thead>
<tr>
<th>Anatomical location</th>
<th>Europe (( n = 277 ))</th>
<th>Central/South America (( n = 182 ))</th>
<th>( \chi^2 ) test(^2 )</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>( N )</td>
<td>350G</td>
<td>%</td>
<td>( N )</td>
</tr>
<tr>
<td>Cervix</td>
<td>52</td>
<td>29</td>
<td>55.77</td>
<td>42</td>
</tr>
<tr>
<td>Vulva</td>
<td>49</td>
<td>29</td>
<td>59.18</td>
<td>17</td>
</tr>
<tr>
<td>Vagina</td>
<td>52</td>
<td>30</td>
<td>57.69</td>
<td>42</td>
</tr>
<tr>
<td>Penis</td>
<td>60</td>
<td>28</td>
<td>46.67</td>
<td>30</td>
</tr>
<tr>
<td>Anal</td>
<td>64</td>
<td>38</td>
<td>59.38</td>
<td>51</td>
</tr>
</tbody>
</table>

The number of samples (\( N \)), the samples with 350G allele (350G), and the percentage for the 350G allele frequencies are represented for each anatomical location for Europe and Central/South America. HPV16, Human papillomavirus type 16.

1Within each anatomical location, differences for the 350G allele frequency in the two geographical origins were assessed using Fisher’s exact test.

2Within each geographical origin, differences for the 350G allele frequency in the different anatomical locations were assessed using chi-square test.
Minor variations in the viral genome may be responsible for important changes regarding increased persistence or viral load [36, 37]. In addition, the adaptive host–pathogen interaction may further condition the differential probability for clearance or for eventual malignization of HPV16 infections [35, 36]. To tackle this connection between viral genotypic diversity and cancer risk, a long-studied candidate has been the T350G(L83V) single-nucleotide polymorphism in the HPV16 genome [38, 39]. In vitro studies have suggested an increased transformation potential for the 83V allele, especially for the HPV16_D lineage [38, 40], although these results may be linked to a specific host genetic background [39]. In European populations, prospective studies in cervical lesions as well as case–control studies have also communicated inconsistent results regarding the involvement of the T350G polymorphism in the persistence and progression to cancer [17, 18, 33, 41].

To address the question of the differential HPV16_E6 350G allele frequencies as a function of the geographical origin and the anatomical location of the cases, we focused exclusively on HPV16_A1-3 samples from Europe and Central/South America. We found that the 350G allele frequency did not significantly differ between anatomical locations for samples from the same geographical origin. In addition, our analysis revealed an increase in 350G allele frequency in samples from Central/South America compared with samples from Europe, consistent for all anatomical locations except for the vulva. This trend is in agreement with previous studies reporting an increased frequency of the 350G allele in Central/South America compared with European populations [31, 32, 33, 34], as well as with the minor contribution of this allele in vulvar and in vaginal lesions [23, 26].

Finally, we estimated the possible influence of the HPV16 variant on the age at cancer diagnosis. The rationale behind is threefold. First, cancer registry data show that cervical cancers are diagnosed earlier than other anogenital cancers associated with HPVs (www.hpvcentre.net). Second, the studies from our group also show that cervical cancers caused by more aggressive HPVs, such as HPV16, HPV18, or HPV45, are diagnosed earlier than cervical cancers caused by other HPVs [4]. Third, the relative contribution of the different HPVs varies depending on the anatomical location of the cancer. Thus, the observed differences in age at diagnosis in HPV-related cancers of different anatomical origin could be linked to specific characteristics of the target tissue and/or to the different prevalence of the underlying viral agents. Making a coherent picture out of all available facts remains, however, a conundrum, because the contribution of HPV16 in noncervical cancers is higher than in cervical cancer: 61% in cervix [4], 62.9% in penis [6], 72.5% in vulva [9], and 75.8% in anus [8]. The only exception to this trend is vaginal cancers.
showing a 57% contribution of HPV16 [10]. One would thus expect that the increased contribution of HPV16 in noncervical cancers would result in earlier age at diagnosis when comparing HPV-related cancers among locations, but this is not the case. Our study design offered a unique opportunity to disentangle both alternatives and to test these hypotheses, as we have gathered a large sample set of HPV16-monoinfected cancers of five different anatomical origins. One explanation could have been that HPV16 variants show different prevalence in cancers from different anatomical locations, but the results communicated here suggest that such differences are minor. Remarkably, our results for the complete series on HPVs and anogenital cancers [4, 6, 8–10] show that differences in age at diagnosis remain unchanged between cervical cancers (diagnosed in the early fifties) and noncervical cancers (diagnosed in the early sixties) when only HPV16 monoinfections are considered, and even after focusing on cancers associated to a single viral lineage, namely the most prevalent HPV16_A1-3. We propose that tissue-specific characteristics of the transitional epithelia at the uterus cervix may underlie the observed trend in age at diagnosis, reflecting an enhanced propensity to infection and/or a lower rate of infection clearing, resulting in an increased vulnerability to HPV16-driven cervical carcinogenesis [42]. The anatomy of anal mucosa encompasses also the transitional epithelia of a squamous-columnar junction, but nevertheless cervical and anal cancers largely differ in incidence and prevalence, age at diagnosis as well as in the repertoire of HPVs and in the contribution of HPV16 to malignization [4, 8]. A particular cellular population in the squamous-columnar junction of the uterus cervix, the so-called cuboidal cells, which retain phenotypic features of embryonic stem cells, is enriched among transformed cells located in the uterus cervix, suggesting that they are implicated in cervical neoplasia after persistent HPVs infection [43]. However, the microanatomy of the anal transformation zone is not identical to that of cervical transformation zone: cells in the cervical squamous-columnar junction are monolayered, they are in direct contact with the basal membrane, and they display a immunophenotype different tumor [44]. Such histochemical differences between cervical and anal transformation zones most likely underlie the large epidemiological differences between cervical and anal HPV-induced cancers in terms of incidence, prevalence, and age at diagnosis.

Despite the large sample size and the sound molecular identification of viral variants, our study suffers from a number of limitations. First, we chose to restrict ourselves to a very homogeneous study subject, namely invasive squamous cell carcinomas containing exclusively HPV16 DNA. By doing so, we could only recover in our repository enough samples from Europe, Central/South America, and Asia, as we did not have access to good quality samples from the African continent. Indeed, a thorough study on the evolution of any human pathogen should aim to sample the host–pathogen interaction there where the genetic diversity of the host is largest, that is, Africa, for humans [45]. Second, we recognize that given the variant variability observed in anal samples, the study would have benefited from an increase in samples collected from Asia. Third, due to the nature of our study, we did not have access to any data regarding patient ethnicity and we were thus constrained to proxy the genetic background of the patient after the geographical origin of the sample. Although the geographical origin of the clinical sample is shown to rather reliably reflect the ethnic origin of the patient, even in admixed populations such as in Central/South America [46], it would have been desirable to generate the genetic data from both human and virus from the same infection. Finally, we have used the broad geographical units defined by the United Nations to stratify geography, but we are nevertheless aware that these units cover large differences in human genetic diversity that may thus result flattened.

In conclusion, our results provide for the first time a sound estimate of the differential contribution of HPV16 variants to anogenital cancers in Europe, Central/South America, and Asia. We identify geographical origin and anatomical location as minor factors for explaining the differential prevalence of HPV16 variants in anogenital cancers. Instead, our results suggest that the increased prevalence of HPV16_A1-3 may reflect a genuinely enhanced fitness for this variant to cause cancer. Only a large prospective series exploring HPV16 variants prevalence on clinically asymptomatic infections, monitoring the initial steps of viral colonization of anogenital mucosas and following differential viral persistence and accounting for the patient’s genetic background, will ultimately provide answers about the extent of the differential fitness of these viral lineages and will help understand the host interplay of the most oncogenic HPV.

Acknowledgments

This work was financially supported by the Fundación Dexeus for Women’s Health grant to IGB, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) to VNP, the Agència de Gestió d’Ajuts Universitaris i de Investigació, AGAUR, Generalitat de Catalunya (2014SGR1077 to XFB), and the Fondo de Investigaciones Sanitarias (FI12/00142 to XFB and SNP). The authors want to thank all participants at the RIS HPV TT and HPV VVAP collaborating centers listed in Table S8.
Conflict of Interest

None declared.

References

1. IARC. 2012. IARC monographs on the evaluation of carcinogenic risks to humans - biological agents. 100B:100B.
Supporting Information

Additional supporting information may be found in the online version of this article:

**Figure S1.** Cumulative pair-wise distance frequencies for HPV16 genes and control region: Pair-wise distances (substitutions per site) are calculated for the full-genome, LCR, and all ORFs of reference sequences. Horizontal plain gray line represents the pair-wise distance 95th percentile. E2 - E4 (E2 minus E4) stands for the E2 gene nonoverlapping with the E4 gene.

**Figure S2.** Mid-point rooted HPV16 best-known maximum likelihood phylogenetic tree, constructed using 109 unique full-length genome sequences. HPV16 lineages are classified into four variants: A, B, C, and D. Bootstrap values above 700 are displayed closed to the corresponding node. GenBank accession numbers are given for all entries.

**Figure S3.** Age at tumor diagnosis for HPV positive, HPV16 single-infected band HPV16 A1-3 invasive squamous cell carcinomas stratified by anatomical location: Box plots represent the median, the 25% and 75% quantiles. Median and range (1.5 × interquantile) are represented in brackets below the box plots. Number of samples is represented in brackets below the anatomical location. HPV16-positive samples include all the types detectable through SPF10-LIPA25 protocol (version 1; Laboratory Biomedical Products, Rijswijk, the Netherlands).

**Table S1.** Sample distribution per anatomical location, geographical region, and country.

**Table S2.** Primer design.

**Table S3.** Likelihood weights for the attribution of each individual sequence to each (sub) variant, number of samples, and percentage.

**Table S4.** Generalized linear model (GLM) and analysis of deviance.

**Table S5.** HPV16 A1-3, A4 and D variant distribution by anatomical location within each geographical area.

**Table S6.** Age at tumor diagnosis for invasive squamous invasive carcinomas HPV positive, HPV negative, HPV16 single infected, and HPV16 A1-A2-A3 stratified by cervix, noncervix (women), and anogenital (men) samples.

**Table S7.** Age at tumor diagnosis for invasive squamous invasive carcinomas HPV positive, HPV16 single infected, and HPV16 A1-A2-A3 stratified by anatomical location.

**Table S8.** Collaborating centers at the RIS HPV TT and HPV VVAP study groups.